Rui Ping Dong
Algemeen Directeur bij Shanghai Haihe Biopharma Co., Ltd.
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Alain Klapholz | M | 67 |
OptMed, Inc.
OptMed, Inc. Medical SpecialtiesHealth Technology OptMed, Inc. is a clinical-stage medical device company, which engages in the development and commercialization of surgical adhesives for the treatment of patients with external and internal wounds. The firm offers products under the brands of BondEase Topical Skin Adhesive and TearRepair Liquid Skin Protectant. Its proprietary technology platform is based on a chemistry called methylidene malonate (MM212), a biocompatible polymer originally designed for drug delivery which has been tested for biocompatibility and adhesive properties in topical and internal applications. The company was founded by Alain Klapholz in 2007 and is headquartered in New York, NY. | 17 jaar |
Steven B. Sands | M | 65 |
OptMed, Inc.
OptMed, Inc. Medical SpecialtiesHealth Technology OptMed, Inc. is a clinical-stage medical device company, which engages in the development and commercialization of surgical adhesives for the treatment of patients with external and internal wounds. The firm offers products under the brands of BondEase Topical Skin Adhesive and TearRepair Liquid Skin Protectant. Its proprietary technology platform is based on a chemistry called methylidene malonate (MM212), a biocompatible polymer originally designed for drug delivery which has been tested for biocompatibility and adhesive properties in topical and internal applications. The company was founded by Alain Klapholz in 2007 and is headquartered in New York, NY. | 13 jaar |
Ervin Braun | M | 69 |
OptMed, Inc.
OptMed, Inc. Medical SpecialtiesHealth Technology OptMed, Inc. is a clinical-stage medical device company, which engages in the development and commercialization of surgical adhesives for the treatment of patients with external and internal wounds. The firm offers products under the brands of BondEase Topical Skin Adhesive and TearRepair Liquid Skin Protectant. Its proprietary technology platform is based on a chemistry called methylidene malonate (MM212), a biocompatible polymer originally designed for drug delivery which has been tested for biocompatibility and adhesive properties in topical and internal applications. The company was founded by Alain Klapholz in 2007 and is headquartered in New York, NY. | 12 jaar |
Curtis L. Cetrulo | M | 54 |
OptMed, Inc.
OptMed, Inc. Medical SpecialtiesHealth Technology OptMed, Inc. is a clinical-stage medical device company, which engages in the development and commercialization of surgical adhesives for the treatment of patients with external and internal wounds. The firm offers products under the brands of BondEase Topical Skin Adhesive and TearRepair Liquid Skin Protectant. Its proprietary technology platform is based on a chemistry called methylidene malonate (MM212), a biocompatible polymer originally designed for drug delivery which has been tested for biocompatibility and adhesive properties in topical and internal applications. The company was founded by Alain Klapholz in 2007 and is headquartered in New York, NY. | 2 jaar |
James Chao | M | 62 |
OptMed, Inc.
OptMed, Inc. Medical SpecialtiesHealth Technology OptMed, Inc. is a clinical-stage medical device company, which engages in the development and commercialization of surgical adhesives for the treatment of patients with external and internal wounds. The firm offers products under the brands of BondEase Topical Skin Adhesive and TearRepair Liquid Skin Protectant. Its proprietary technology platform is based on a chemistry called methylidene malonate (MM212), a biocompatible polymer originally designed for drug delivery which has been tested for biocompatibility and adhesive properties in topical and internal applications. The company was founded by Alain Klapholz in 2007 and is headquartered in New York, NY. | 2 jaar |
Martin S. Sands | M | 63 |
OptMed, Inc.
OptMed, Inc. Medical SpecialtiesHealth Technology OptMed, Inc. is a clinical-stage medical device company, which engages in the development and commercialization of surgical adhesives for the treatment of patients with external and internal wounds. The firm offers products under the brands of BondEase Topical Skin Adhesive and TearRepair Liquid Skin Protectant. Its proprietary technology platform is based on a chemistry called methylidene malonate (MM212), a biocompatible polymer originally designed for drug delivery which has been tested for biocompatibility and adhesive properties in topical and internal applications. The company was founded by Alain Klapholz in 2007 and is headquartered in New York, NY. | 13 jaar |
Hai Ying Liu | M | 48 |
Shanghai Haihe Biopharma Co., Ltd.
Shanghai Haihe Biopharma Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China. | 7 jaar |
Zhi Gang Tian | M | 68 |
Shanghai Haihe Biopharma Co., Ltd.
Shanghai Haihe Biopharma Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China. | 4 jaar |
Jun Yan | M | 42 |
Shanghai Haihe Biopharma Co., Ltd.
Shanghai Haihe Biopharma Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China. | 4 jaar |
Qiang Zhao | M | 61 |
Shanghai Haihe Biopharma Co., Ltd.
Shanghai Haihe Biopharma Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China. | 4 jaar |
Kenneth Burhop | M | 71 |
OptMed, Inc.
OptMed, Inc. Medical SpecialtiesHealth Technology OptMed, Inc. is a clinical-stage medical device company, which engages in the development and commercialization of surgical adhesives for the treatment of patients with external and internal wounds. The firm offers products under the brands of BondEase Topical Skin Adhesive and TearRepair Liquid Skin Protectant. Its proprietary technology platform is based on a chemistry called methylidene malonate (MM212), a biocompatible polymer originally designed for drug delivery which has been tested for biocompatibility and adhesive properties in topical and internal applications. The company was founded by Alain Klapholz in 2007 and is headquartered in New York, NY. | 2 jaar |
de la Fuente Veronica | M | - |
OptMed, Inc.
OptMed, Inc. Medical SpecialtiesHealth Technology OptMed, Inc. is a clinical-stage medical device company, which engages in the development and commercialization of surgical adhesives for the treatment of patients with external and internal wounds. The firm offers products under the brands of BondEase Topical Skin Adhesive and TearRepair Liquid Skin Protectant. Its proprietary technology platform is based on a chemistry called methylidene malonate (MM212), a biocompatible polymer originally designed for drug delivery which has been tested for biocompatibility and adhesive properties in topical and internal applications. The company was founded by Alain Klapholz in 2007 and is headquartered in New York, NY. | - |
Zhe Wang | M | 32 |
Shanghai Haihe Biopharma Co., Ltd.
Shanghai Haihe Biopharma Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China. | 4 jaar |
Jian Ding | M | 71 |
Shanghai Haihe Biopharma Co., Ltd.
Shanghai Haihe Biopharma Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China. | 13 jaar |
Hai Ying Zhu | F | 47 |
Shanghai Haihe Biopharma Co., Ltd.
Shanghai Haihe Biopharma Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China. | 4 jaar |
Qun Guo | F | 57 |
Shanghai Haihe Biopharma Co., Ltd.
Shanghai Haihe Biopharma Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China. | 6 jaar |
Jia Hou | F | 41 |
Shanghai Haihe Biopharma Co., Ltd.
Shanghai Haihe Biopharma Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China. | 7 jaar |
Lin Xia | M | 42 |
Shanghai Haihe Biopharma Co., Ltd.
Shanghai Haihe Biopharma Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China. | 7 jaar |
Min Fang | M | 45 |
Shanghai Haihe Biopharma Co., Ltd.
Shanghai Haihe Biopharma Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China. | 4 jaar |
Ying Luo | F | 53 |
Shanghai Haihe Biopharma Co., Ltd.
Shanghai Haihe Biopharma Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China. | 4 jaar |
Zhi Jian Chen | M | 69 |
Shanghai Haihe Biopharma Co., Ltd.
Shanghai Haihe Biopharma Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China. | 6 jaar |
Ciaran McArdle | M | - |
OptMed, Inc.
OptMed, Inc. Medical SpecialtiesHealth Technology OptMed, Inc. is a clinical-stage medical device company, which engages in the development and commercialization of surgical adhesives for the treatment of patients with external and internal wounds. The firm offers products under the brands of BondEase Topical Skin Adhesive and TearRepair Liquid Skin Protectant. Its proprietary technology platform is based on a chemistry called methylidene malonate (MM212), a biocompatible polymer originally designed for drug delivery which has been tested for biocompatibility and adhesive properties in topical and internal applications. The company was founded by Alain Klapholz in 2007 and is headquartered in New York, NY. | - |
Burrows H.F. | M | - |
OptMed, Inc.
OptMed, Inc. Medical SpecialtiesHealth Technology OptMed, Inc. is a clinical-stage medical device company, which engages in the development and commercialization of surgical adhesives for the treatment of patients with external and internal wounds. The firm offers products under the brands of BondEase Topical Skin Adhesive and TearRepair Liquid Skin Protectant. Its proprietary technology platform is based on a chemistry called methylidene malonate (MM212), a biocompatible polymer originally designed for drug delivery which has been tested for biocompatibility and adhesive properties in topical and internal applications. The company was founded by Alain Klapholz in 2007 and is headquartered in New York, NY. | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Richard Berenson Stone | M | 81 |
OptMed, Inc.
OptMed, Inc. Medical SpecialtiesHealth Technology OptMed, Inc. is a clinical-stage medical device company, which engages in the development and commercialization of surgical adhesives for the treatment of patients with external and internal wounds. The firm offers products under the brands of BondEase Topical Skin Adhesive and TearRepair Liquid Skin Protectant. Its proprietary technology platform is based on a chemistry called methylidene malonate (MM212), a biocompatible polymer originally designed for drug delivery which has been tested for biocompatibility and adhesive properties in topical and internal applications. The company was founded by Alain Klapholz in 2007 and is headquartered in New York, NY. | - |
Xiang Dong He | M | 61 |
Kyushu University
| 3 jaar |
Shinya Tamura | M | 57 |
Kyushu University
| 2 jaar |
Yi Ran Huang | M | 69 |
Jiangxi Medical College
| 4 jaar |
Mohammad Jonaid Shafiq | M | 63 |
Kyushu University
| 3 jaar |
Jian Liu | F | 59 |
Kyushu University
| 4 jaar |
Xiao Ming Wu | M | 70 |
Kyushu University
| 4 jaar |
Shigeru Nakashima | M | - |
Kyushu University
| 4 jaar |
Robert Karl | M | - |
Merck & Co.
| 1 jaar |
Kyohei Morita | M | - |
Kyushu University
| 4 jaar |
Masanori Yoshitake | M | 51 |
Kyushu University
| 4 jaar |
Jue Ren Lou | M | 71 |
Jiangxi Medical College
| 5 jaar |
Huai Dong Wang | M | 59 |
Kyushu University
| 3 jaar |
Jian Ding | M | 71 |
Kyushu University
| 3 jaar |
Makoto Inoue | M | - |
Kyushu University
| 3 jaar |
Hong Chang | M | 58 |
Jiangxi Medical College
| 3 jaar |
Yi Rao | M | 61 |
Jiangxi Medical College
| 4 jaar |
Tetsuo Mitsuyasu | M | - |
Kyushu University
| 4 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
China | 17 | 41.46% |
Verenigde Staten | 12 | 29.27% |
Japan | 12 | 29.27% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Rui Ping Dong
- Persoonlijk netwerk